Collaboration Launched to Identify Diagnostic Biosignatures in Early Alzheimer's Disease Detection

A research agreement has been initiated to identify a biosignature associated with Alzheimer's disease. This research effort will combine expertise in data integration, informatics, genomics, and imaging. Its objective will be to find a biosignature that may enable the detection of Alzheimer's disease before the onset of clinical symptoms.

The collaboration is between GE Healthcare (Chalfont St. Giles, UK) and Janssen Pharmaceutica NV, LLC (Beerse, Belgium) is part of a wide range of diagnostic solutions that GE Healthcare is developing in the Alzheimer's field. "GE Healthcare has a global commitment to advancing clinical knowledge and providing innovations that may accelerate diagnosis of Alzheimer's disease and transform patient management," said Pascale Witz, president and CEO, GE Healthcare, medical diagnostics. "The collaboration we are announcing today is part of this effort to understand Alzheimer's. Finding a biosignature, essentially a collection of biomarkers, that identifies people at risk from the disease, would enable physicians to make more informed decisions about patient care. Importantly, it might also accelerate the development of successful treatments for the disease."

Phase 3 trials are underway for GE Healthcare's amyloid positron emission tomography (PET) imaging compound Flutemetamol.

Related Links:
GE Healthcare
Janssen Pharmaceutica